SR-Exenatide (PT320)

PT320 is a sustained-release Exenatide (GLP1 agonist) for biweekly injection (Q2W). Due to its short half-life of 2.4 hours in the plasma of Exenatide, Peptron has developed a long-acting SR-Exenatide (PT320), resulting in sustained elevations of Exenatide for 20 days. With the result of preclinical and Phase I study of PT320, Peptron is testing the efficacy of PT320 of Parkinson's disease in the on-going Phase II trial.

MUC-1 Targeting Therapeutic Antibody (PAb-001)

PAb-001 is the First-In-Class Novel Therapeutic Antibody, targeting OT-MUC1 for Cancer Therapy.